Terry-Ann Burrell, a financial industry veteran, is Chief Financial Officer of Beam. Prior to Beam, Ms. Burrell spent 11 years with J.P. Morgan, most recently as a Managing Director in the healthcare investment banking group. There, she had broad coverage across the biotechnology and pharmaceutical industries, helping to execute over $10 billion in equity and equity linked financings and more than $50 billion in M&A transactions. She was instrumental in advising clients on transaction considerations, including strategic rationale, valuation and structuring, and engaged with more than 100 companies during her tenure. Prior to J.P. Morgan, Ms. Burrell worked in equity research at Citigroup, where she covered specialty pharmaceuticals and generics. Ms. Burrell holds an MBA from New York University Leonard N. Stern School of Business and a B.A. from Harvard University.

Komal Joshi is the head of strategic finance and investor relations at Jounce Therapeutics, a clinical-stage immunotherapy company that is developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to cancer patients. Prior to Komal’s transition to industry, she spent 15+ years in financial services, beginning with her role as a sell-side equity research analyst. Komal then moved to healthcare investment banking where she executed on capital raising and M&A advisory for emerging to large cap healthcare product and services companies. Altogether, she brings almost 20 years of increasing industry and financial services experiences. Komal has a BS in Finance from Boston College and an MBA from Columbia Business School.

David Lubner is an accomplished financial leader in the biotech/life sciences space. He served as executive vice president and chief financial officer of Ra Pharmaceuticals, Inc., acquired by UCB, S.A. in April 2020, from 2016 until May 2020. Before joining Ra Pharma, David served as a member of the senior management team of Tetraphase Pharmaceuticals, Inc. and PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company, which was acquired by IMS Health in 2015 and at ProScript, Inc., where Velcade® (bortezomib), a therapy widely used for treatment of the blood cancer, multiple myeloma, was discovered. He serves on the Board of Directors of Dyne Therapeutics Inc., focused on developing life-transforming therapies for inherited muscle diseases; Gemini Therapeutics Inc., a clinical stage precision medicine company developing innovative treatments for age-related macular degeneration (AMD) and, Ichnos Sciences. He previously served on the Board of Directors of Nightstar Therapeutics plc (NASDAQ: NITE), focused on the development of one-time retinal gene therapies for patients suffering from rare inherited retinal diseases acquired by Biogen in June 2019. David is a Certified Public Accountant. He received his B.S. in business administration from Northeastern University and an M.S. in taxation from Bentley University.

Pauline McGowan joined Cygnal Therapeutics in January 2019 as Senior Vice President of Finance. She has more than 20 years of financial planning, accounting, and operational experience in the life sciences industry. Most recently, Pauline served as Head of Finance at Ginkgo Bioworks during a period of rapid growth, including a $275M Series D financing and $100M joint venture with Bayer. Prior to Ginkgo Bioworks, Pauline served as Vice President of Finance at Concert Pharmaceuticals. She played a lucrative role in joining the privately held biotech company in 2007, while also managing its governance and SEC Compliance through S-1 filing and successful IPO. She began her professional career at PricewaterhouseCoopers LLP. Pauline holds a B.S. in Business Administration from Villanova University and was licensed as a Certified Public Accountant in Massachusetts.

Hunter Smith was appointed to serve as interim Chief Executive Office in March 2020. He has been our Chief Financial Officer since August 2017, and during that time he led the company in an initial public offering that netted the Company $125 million, as well as two follow-on public offerings that netted approximately $346 million. As a member of the management team, Hunter has played a critical role in charting Rhythm’s corporate strategy and managing the company’s performance. He has 20 years’ experience in global finance and management roles across multiple industries and financial disciplines, including expertise in business analysis and planning, mergers and acquisitions, capital raising and investor relations. He joined Rhythm from Celgene Corporation, where he served as Vice President, Finance and Chief Financial Officer of the Company’s Inflammation and Immunology Business Unit. In this role, Hunter provided finance leadership for the global launch of Otezla®, co-led the integration of Receptos, Inc. following its acquisition by Celgene, and led global business planning and analysis for commercial affiliates and clinical study activities in over 16 countries. Before joining Celgene, Hunter worked for fourteen years in roles of increasing responsibility at Bunge Limited, including Director of Investor Relations, Chief Financial Officer–Asia, Chief Risk Officer, Corporate Treasurer, and Chief Financial Officer of Bunge’s Sugar and Bioenergy Segment. He holds an MBA in Finance from NYU’s Stern School of Business and a BA in History, with honors, from Northwestern University. Hunter served as an Independent Director of Genessee & Wyoming Inc. and as a member of the Compensation Committee, until its acquisition by Brookfield Infrastructure Partners in December 2019.

Mr. Sundaram has served as a member of the Axovant Gene Therapies board since June 2019. He was most recently the Chief Financial Officer at Nightstar Therapeutics, until its acquisition by Biogen in June 2019. While at Nightstar, he was responsible for corporate finance and operations, business development, and strategy. He helped lead the execution of multiple equity offerings, as well as licensing and M&A transactions. Prior to joining Nightstar, Mr. Sundaram was the Vice President and Head of Business and Corporate Development at Intercept Pharmaceuticals, Inc. Previously, Mr. Sundaram spent 13 years in the healthcare investment banking groups at Lehman Brothers/Barclays, Citigroup and Lazard. Mr. Sundaram holds a B.S. in Computer Engineering and a B.A. in Economics from Brown University.